<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653120</url>
  </required_header>
  <id_info>
    <org_study_id>40451</org_study_id>
    <nct_id>NCT00653120</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Propranolol Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Propranolol 160 mg With That of Inderal-LA Propranolol 160 mg in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SFBC Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose bioavailability of Propranolol 160 Mg ER capsules with Inderal-La&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single -dose bioavailability of Par Propranolol 160 Mg ER capsules with Wyeth&#xD;
      Pharmaceuticals, Inderal-LA, Propranolol under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>To Determine Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Par Products under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Wyeth Pharmaceuticals product under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>ER capsules, 160 mg, single-dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Inderal-LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inderal-LA</intervention_name>
    <description>ER capsules, 160 mg, single-dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Propranolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects enrolled in the study will be members of the community at large. The&#xD;
             Recruitment advertisements may use various media types (E.g. ratio, newspapers, SFBC&#xD;
             Anapharm Website, SFBC Anapharm volunteer's database). Subjects must meet all the&#xD;
             following criteria in order to be included in the study.&#xD;
&#xD;
          -  Male and female, non-smoker, 18 years of age and older&#xD;
&#xD;
          -  Capable of consent&#xD;
&#xD;
          -  BMI â‰¥ 19.0 and &gt; 30.0 kg/ m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects to whom any of the following applies will be excluded from the study.&#xD;
&#xD;
          -  Clinically significant illness within 4 weeks prior to the administration of the study&#xD;
             medication&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Medical Sub- Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 100 or over 140 mmHg, diastolic blood pressure lower than 60 or&#xD;
             over 90 mmHg, or heart rate less than 60 or over 100 bpm) at screening.&#xD;
&#xD;
          -  History of significant alcohol abuse or drug abuse within one year prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Regular use of alcohol within six months prior to the screening visit (more than&#xD;
             fourteen units of alcohol per week [ 1 Unit = 150mL of wine, 360 mL of beer, or 45mL&#xD;
             of 40% alcohol])&#xD;
&#xD;
          -  Use of soft drugs ( such as marijuana) within 3 months prior to the screening visit or&#xD;
             hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the&#xD;
             screening visit or positive urine drug at screening.&#xD;
&#xD;
          -  History of allergic reactions to heparin, propranolol, or other related drugs.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin,glucocorticoids , omerprazole;&#xD;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,&#xD;
             imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney&#xD;
             disease, or other conditions known as interface with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, hematologic, psychiatric, or metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of a study&#xD;
             medication or over the counter products (including natural food supplements, vitamins,&#xD;
             garlic as a supplement) within 7 days prior to administration of study medication,&#xD;
             except for topical products without systemic absorption and hormonal contraceptive.&#xD;
&#xD;
          -  Difficulty to swallow study medication.&#xD;
&#xD;
          -  Use of any tobacco products in the 6 months proceeding drug administration.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Medical Sub- Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug (other than contraceptives) within 3&#xD;
             months prior to administration of study medication.&#xD;
&#xD;
          -  Donation of plasma (500 Ml) within 7 days to drug administration. Donation or loss of&#xD;
             whole blood (excluding the volume of blood drawn during the screening procedures of&#xD;
             this study) prior to administration of the study medication as follows.&#xD;
&#xD;
          -  50mL to 300mL of whole blood within 30 days, 301 mL to 500 ml of whole blood within&#xD;
             45days or more than 500 mL of whole blood within 56 days prior to drug&#xD;
             administration..&#xD;
&#xD;
          -  History bronchial asthma and bronchospastic diseases.&#xD;
&#xD;
          -  History of known presence of cardiogenic shock, sinus bradycardia, Wolff-Parkinson&#xD;
             White Syndrome, congestive heart failure or angina.&#xD;
&#xD;
          -  Clinically significant history of diabetes.&#xD;
&#xD;
          -  Clinically significant history of hyperthyroidism.&#xD;
&#xD;
          -  Breast- feeding subject.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening.&#xD;
&#xD;
          -  Female subjects of childbearing potential having unprotected sexual intercourse with&#xD;
             any non- sterile male partner (i.e. male who ahs not been sterilized by vasectomy for&#xD;
             al least 6 months) within 14 days prior to study drug administration. Acceptable&#xD;
             methods of contraception:&#xD;
&#xD;
          -  Intra-uterine contraceptive device (place al least 4 weeks prior to study drug&#xD;
             administration)&#xD;
&#xD;
          -  Condom or diaphragm. + spermicide&#xD;
&#xD;
          -  Hormonal contraceptives (starting al least 4 weeks prior to study administration)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Audet</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Sainte- Foy</city>
        <state>Quebec</state>
        <zip>G1V2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>April 1, 2008</last_update_submitted>
  <last_update_submitted_qc>April 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alfred Elvin/ Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence, Propranolol ER capsules, fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

